{"id":175484,"date":"2026-09-28T14:36:09","date_gmt":"2026-09-28T14:36:09","guid":{"rendered":"https:\/\/www.europesays.com\/dk\/175484\/"},"modified":"2026-09-28T14:36:09","modified_gmt":"2026-09-28T14:36:09","slug":"novo-nordisk-a-s-share-repurchase-programme-102","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/dk\/175484\/","title":{"rendered":"Novo Nordisk A\/S &#8211; share repurchase programme"},"content":{"rendered":"<p>Bagsv\u00e6rd, Denmark, 28 September 2026\u00a0&#8211; On 6 May 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596\/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016\/1052 of 8 March 2016 (the &#8220;Safe Harbour Rules&#8221;). This programme is part of the overall share repurchase programme of up to DKK 15 billion to be executed during a 12-month period beginning 4 February 2026.<\/p>\n<p>Under the programme initiated 6 May 2026, Novo Nordisk will repurchase B shares for an amount up to DKK 11,200,000,010.45 in the period from 6 May 2026 to 1 February 2027.<\/p>\n<p>Since the announcement 21 September, the following transactions have been made:<\/p>\n<p>\u00a0Number of<\/p>\n<p>B shares<\/p>\n<p>Get the latest news<br \/>\n                <br class=\"br-line\"\/><br \/>\n                delivered to your inbox<\/p>\n<p>Sign up for The Manila Times newsletters<\/p>\n<p>            By signing up with an email address, I acknowledge that I have read and agree to the <a href=\"https:\/\/www.manilatimes.net\/terms-of-service\" title=\"Terms of Service\" rel=\"nofollow noopener\" target=\"_blank\">Terms of Service<\/a> and <a href=\"https:\/\/www.manilatimes.net\/privacy-policy\" title=\"Privacy Policy\" rel=\"nofollow noopener\" target=\"_blank\">Privacy Policy<\/a>.<\/p>\n<p>Average<\/p>\n<p>purchase price<\/p>\n<p>Transaction<\/p>\n<p>value, DKK<\/p>\n<p>Accumulated, last announcement19,415,000\u00a05,829,922,94621 September 2026250,000267.4166,853,08422 September 2026250,000258.3064,575,34123 September 2026220,000256.1756,357,07724 September 2026240,000250.4260,101,97425 September 2026245,000253.1962,031,620Accumulated under the programme20,620,000\u00a06,139,842,042 The details for each transaction made under the share repurchase programme are published on <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=G8B7ugENUWqjZLcMjiLcvfuAPKdmZImuPVmZIm2beVmHdZCjjpR5uifwEBJq-ViAxgD9xW3crRrIZHej8l7P2lalLghV4wNv04m9TYoPv1ezxgN1SGyeJBHnx612XZLOdRjEpuMi1PpaybMaTu7XrQtuvr2IUr498sXrrinnuf0=\" rel=\"nofollow noopener\" target=\"_blank\">novonordisk.com<\/a>.<\/p>\n<p>With the transactions stated above, Novo Nordisk owns a total of 49,419,876 B shares of DKK 0.10 as treasury shares, corresponding to 1.1% of the share capital. The total amount of A and B shares in the company is 4,465,000,000 including treasury shares.<\/p>\n<p>Novo Nordisk expects to repurchase B shares for an amount up to DKK 15 billion during a 12-month period beginning 4 February 2026. As of 25 September 2026, Novo Nordisk has since 4 February 2026 repurchased a total 35,379,179 B shares at an average share price of DKK 280.95 per B share equal to a transaction value of DKK 9,939,842,031.<\/p>\n<p>Novo is the global healthcare company that believes lasting health starts now. For over a century, we\u2019ve combined leading scientific expertise with a deep understanding of people\u2019s lives. We develop treatments and support that help millions of people make progress they can see, feel and sustain now and in the future. Every day, over 67,000 employees around the world advance our purpose to drive change for lasting health. Through our partnerships, programmes and investments, we\u2019re working to prevent disease, expand access to treatments and reduce our environmental impact to help even more people live healthier lives. Novo Nordisk&#8217;s B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=G8B7ugENUWqjZLcMjiLcvRXYC1xOP8k7HkmqJLSjCAz221lfuUHPqUfy358ZUqCL0J6HmpzhBzbi7p0mM8zXVYAwE4q1xU5EDikSXCiWb9E=\" rel=\"nofollow noopener\" target=\"_blank\">novonordisk.com<\/a> and follow us on <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=-Gu2qKP2EwgTd-sgq_1xGW3x7L7SpcHT3Hj6vKczGixfzJyXvs89jIbEZtLRjE1H0eaLc9wHfgXKC9_NnzgXzN2qjD_6Z5gcbLhXPTOrNmY=\" rel=\"nofollow noopener\" target=\"_blank\">Instagram<\/a>, <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=CZrx-b935OKTQwtPmMYfXF0_HKAjhxnu24422CGqXVa3NrD8diGWnSmBswtMDmmEYXnQe3kDiqy6EbhqpEP2qBTTbRo7Bt67qB4jv_abvjxE_x74nKqAsRujIdQbaHx1\" rel=\"nofollow noopener\" target=\"_blank\">LinkedIn<\/a>, <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=F2ysjyer4S1FCaIdFtUGzxjtDoBVNLvxwHUg3CFnbGlOkTLNsdwIXUHtPaA1sc4ycQShUuMWa8Ogsvhco-Iq4jCDCrodcA-_mZ9zadhJ94U=\" rel=\"nofollow noopener\" target=\"_blank\">TikTok<\/a>, <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ffIzyXgwih3W_pwnaxvHiDUS0aSEykWpR7YF1JwYTK58hE9XNpVSxV0eJQVTCUZjAKALek8jDONRXn9aSrcop3KXNAi8IQDx4knVLEhGdCo=\" rel=\"nofollow noopener\" target=\"_blank\">Facebook<\/a>, <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=pUERMyHy1Z1gb2NsYTCL6gAl-0REzrzq-tElrZBuzg9NhV8egM-zgZT9TNQDj0pq8tSnGgfltEDI8sZaGwiSEA==\" rel=\"nofollow noopener\" target=\"_blank\">X<\/a> and <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=cIU-td941_sqqsYBwpDrVOa7g59iWreU9eWkaCfKfvQoooL7ann1B-5PbnFqkT-UGTlibDyEomRvseiPZ5p8zm2pbR_vTqiwqGaZgbguJh0=\" rel=\"nofollow noopener\" target=\"_blank\">YouTube<\/a>.\u00a0<\/p>\n<p>Contacts for further information<\/p>\n<p> Company announcement No 58 \/ 2026<\/p>\n<p>Attachments<\/p>\n<p><a target=\"_blank\" href=\"https:\/\/www.globenewswire.com\/Tracker?data=Ejjsi7og5V6UmYEkDXZUEIIqrKvmgubTafe-y4SdvRyA_YgkGAuPuEY9XNuGbUn_rHxWIHTbL8NOqjXvimbvzorQxoKZlKzKQ1J9RQunxp17k02ZIYOsIimYu_oPPteNE1qrxIZG28GwwdEd8x-2STH5hSCyQ9NSbggCVz1w9mm_5A-wyU9Hal9gGMMhR6xf\" rel=\"nofollow noopener\">CA260928_Safe Harbour<\/a><\/p>\n<p><a target=\"_blank\" href=\"https:\/\/www.globenewswire.com\/Tracker?data=Ejjsi7og5V6UmYEkDXZUEOLG15SaA1ZJ85Xq08BT55TDX-uCcG7PgLZ0WpcLYvXizk5-7xqU6a9HsX59Jyy0n1g2LkCRuxrW_G2gTxYMRay--yurIvACgOeWZcvTb1qGIYD4PgwnEC3_-m4h9qG5Q598exp4TN_fKrJNow18zJWyRWyGYt6kIsUq5ZJLuYF9ineawO1r6E5JklP5QOJd-g==\" rel=\"nofollow noopener\">CA260928_Safe harbour transaction details<\/a><\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/www.europesays.com\/dk\/wp-content\/uploads\/2026\/09\/1790606169_340_Novo-Nordisk-A-S.png\"\/><\/p>\n","protected":false},"excerpt":{"rendered":"Bagsv\u00e6rd, Denmark, 28 September 2026\u00a0&#8211; On 6 May 2026, Novo Nordisk initiated a share repurchase programme in accordance&hellip;\n","protected":false},"author":2,"featured_media":175485,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[271],"tags":[1128,26,5691,3845,272,1132,50190,1130],"class_list":["post-175484","post","type-post","status-publish","format-standard","has-post-thumbnail","category-novo-nordisk","tag-a-s","tag-denmark","tag-nordisk","tag-novo","tag-novo-nordisk","tag-programme","tag-repurchase","tag-share"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@dk\/117349173942240705","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/175484","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/comments?post=175484"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/175484\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media\/175485"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media?parent=175484"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/categories?post=175484"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/tags?post=175484"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}